Please provide your email address to receive an email when new articles are posted on . Although active surveillance is acceptable for low-risk prostate cancers, the strategy may be risky for patients ...

Utilization of active surveillance (AS) for prostate cancer is increasing. Optimal selection criteria for this approach are undefined and questions remain on how best to expand inclusion beyond ...

March 4, 2010 — The results of a landmark study often represent the definitive word clinically. For the landmark Radiation Therapy Oncology Group (RTOG) 94-08 study, which evaluated short-term hormone ...

Survival curves separated as early as 4 to 5 years after initiation of active surveillance or active treatment, investigators reported. Active surveillance (AS) should be cautiously offered to men ...

CHICAGO -- Adding a short course of androgen deprivation therapy (ADT) to dose-escalated radiotherapy (RT) led to a mixed bag of outcomes in intermediate-risk prostate cancer, according to a large ...

Pet Therapy: How the Cat I Never Wanted Saved My Life Malone et al 1 performed a randomized trial comparing 6 months of neoadjuvant versus adjuvant androgen deprivation therapy (ADT) combined with ...

Robert De Niro, Warren Buffett and Ben Stiller had prostate cancer, detected at an early-enough stage to allow for recovery. Their treatments included surgery and radiation -- which may sometimes ...

The rate of active surveillance as initial treatment increased from 2.0% in 2010 to 8.6% in 2020. The use of active surveillance in patients with intermediate-risk prostate cancer has increased in ...

Please provide your email address to receive an email when new articles are posted on . Men with low- or intermediate-risk prostate cancer achieved similar quality-of-life outcomes whether they ...

Adding 6 months of neoadjuvant deprivation therapy (NADT) doesn’t seem to add any benefit for patients with intermediate-risk prostate cancer treated with external-beam radiation therapy (EBRT), ...

ARLINGTON, Va., September 29, 2023 — People with intermediate risk, localized prostate cancer can be treated as effectively using fewer and higher doses of radiation therapy delivered over five ...